ANI Pharmaceuticals Appoints New Board Member
This article was originally published in Scrip
ANI Pharmaceuticals Inc. has appointed Peter A. Lankau to its board of directors. Currently Lankau is on the board of advisors of Orchard Venture Partners and chair of the board at Phosphagenics Ltd. Prior to this, he was executive chair at Nautilus Neurosciences, Inc. and before this he was chair and CEO of Logical Therapeutics, Inc. Previously, he was CEO and director of Endo Pharmaceuticals Inc.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.